The life sciences R&D engine is rapidly digitizing, and clinical development software now sits at its center. This report sizes the global clinical trials technology market at nearly US$6.5 billion for 2025 (8-10% CAGR) and dissects its four core segments – Electronic Data Capture (EDC), Clinical Trial Management Systems (CTMS), Decentralized Clinical Trial (DCT) platforms, and clinical data and analytics suites. This study maps demand surges in oncology, rare disease, neurology, and obesity trials and examines the contrasting pressures of build-versus-buy debates and heightened data privacy scrutiny. Beyond market numbers, the report spotlights whitespaces such as end-to-end interoperability, real-time visualization, and true low/no-code configurability, analyzes segment-specific product trends (AI-driven EDC validation, next-generation CTMS forecasting, patient-centric DCT designs, and unified analytics hubs), and details the investment priorities sponsors and CROs are setting for 2025. A forward-looking section explores generative AI and agentic AI use cases, from autonomous protocol design to real-time safety monitoring, and outlines adoption stages and success prerequisites. These insights equip stakeholders to refine technology roadmaps, close capability gaps, and accelerate drug-development timelines. Scope Industry: life sciences Geography: global Contents In this report, we examine: 2023-25 clinical technology market size, growth, and segment mix Therapeutic area demand and shifting R&D spend Growth drivers and inhibitors Persistent gaps and sponsor-sourcing criteria Product-innovation themes across EDC, CTMS, DCT, and analytics High-potential generative AI and agentic AI applications and adoption stages 2025 investment priorities for sponsors, CROs, and technology providers

Increasing trial complexity, growing data volumes, and the rise of decentralized and real-world data sources are fundamentally transforming the clinical trial landscape. Traditional Clinical Data Management (CDM) processes are largely manual and rely on siloed data systems, making them inefficient and error-prone. In response, AI is emerging as an essential force in reshaping CDM. This Viewpoint analyzes the transformative roles of AI, generative AI and agentic AI, in modernizing CDM operations. It details how AI is enabling intelligent automation across the trial lifecycle, from protocol design and CRF setup to real-time data validation, anomaly detection, and regulatory documentation. Agentic AI is further pushing boundaries by enabling adaptive, autonomous decision-making with minimal human intervention. These capabilities not only reduce cycle times and improve data quality but also fundamentally shift how clinical teams manage, interact with, and derive insights from data. The report also offers a landscape view of AI-powered solutions across provider types, including global CROs, specialist CDM firms, and IT/BPO players. It outlines key cases, priority capabilities, and practical considerations for life sciences enterprises looking to integrate AI into their CDM strategies. Industry Life Sciences BPS Geography Global Contents In this report, we examine: The limitations of traditional CDM models in an increasingly complex data environment The role of AI, generative AI, and agentic AI in transforming CDM operations Key use cases across the CDM value chain The provider landscape, including differentiated value propositions across CROs, IT/BPO firms, and niche players Future outlook on multi-agent collaboration, autonomous compliance, and intelligent patient engagement through agentic AI Strategic considerations for evaluating and implementing AI-powered CDM solutions Memberships Clinical Development Technology Life Sciences Business Process Sourcing and Vendor Management

The average drug development timeline, from discovery to the commercial launch of a new drug, is between 12 and 15 years. To overcome long timelines, high demand, clinical trial failures, and complex biomanufacturing processes, the industry is adopting AI. Advances in gen AI, neural networks, and LLMs enable improvement in predictive AI models. These predictive models can save significant time and costs in drug development while meeting the expected accuracy and quality levels in clinical outcomes. Biopharma companies are adopting AI-driven platforms to accelerate drug-target discovery, lead identification, lead optimization, and clinical trials across modalities. AI is also transforming advanced therapeutics, clinical decisions, regulatory assistance, and drug delivery system design and formulation. This report analyzes AI’s role in biopharma and explores AI’s technology advances, impact, and future evolution in drug discovery and bioprocessing. Scope Geography: all Industry: healthcare, pharmaceutical, AI in drug discovery, and AI in bioprocessing Contents In this report, we examine: AI in the biopharma industry Key factors driving R&D and AI adoption Key technology developers and adopters and innovation landscape The future trajectory of AI in biopharma

As an increasing number of pharmaceutical companies experiment with different ways to cut costs while boosting productivity amid the pandemic, the industry is increasingly switching to cloud-based technologies. In this scenario, Veeva has become indispensable for the life sciences industry, helping life sciences enterprises manage customer databases, track drug developments, and organize clinical trials. Veeva entered the life sciences market with its Commercial Cloud business, including the core Customer Relationship Management (CRM) offering, which has now transitioned into a mature product with a market share of about 80% across all global pharmaceutical companies. Lately, Veeva has been experiencing increasing demand for its Development Cloud (R&D) suite, which now drives more than half of its total revenue. This report focuses on changing market dynamics, emerging service provider trends, and guidance on devising the right market entry strategy for Veeva services Scope Industry: life sciences Services: Veeva services Geography: global Contents This report comprises three sections, each containing insights on the Veeva services market: Veeva Systems’ product performance and future growth outlook Veeva services market size and insights on service providers The right market entry strategy for the Veeva services market Membership(s) Life Sciences Information Technology Sourcing and Vendor Management

As an increasing number of pharmaceutical companies experiment with different ways to cut costs and boost productivity amid the pandemic, the industry is increasingly switching to cloud-based technologies. In this scenario, Veeva has emerged as indispensable for the life sciences industry, helping life sciences enterprises manage customer databases, track drug developments, and organize clinical trials. Veeva’s expansion in the industry, as well as newer industries such as consumer goods, has resulted in the next wave of growth in corresponding IT services. Veeva-specific IT services is estimated to be a US$2 billion opportunity by 2025, and service providers are building strong Veeva-specific solutions to expedite clients’ time-to-market. In this report, we analyze 15 IT service providers’ Veeva services capabilities. These service providers are classified as Leaders, Major Contenders, and Aspirants based on their positioning on the Everest Group PEAK Matrix® – a composite index of distinct metrics related to a provider’s capability and market impact. Scope Industry: life sciences and pharmaceutical Geography: global Contents This report provides: An assessment of Veeva service providers on several capability and market success-related dimensions A detailed profile of each service provider, including capability overview, case studies, recent developments, and enterprise sourcing considerations Membership(s) Life Sciences Information Technology Sourcing and Vendor Management

As an increasing number of pharmaceutical companies experiment with different ways to cut costs while boosting productivity amid the pandemic, the industry is increasingly switching to cloud-based technologies. In this scenario, Veeva has become indispensable for the life sciences industry, helping life sciences enterprises manage customer databases, track drug developments, and organize clinical trials. Veeva entered the life sciences market with its Commercial Cloud business, including the core Customer Relationship Management (CRM) offering, which has now transitioned into a mature product with a market share of about 80% across all global pharma companies. Lately, Veeva has been experiencing an increasing demand for its Development Cloud (R&D) suite, which now drives more than half of its total revenue. With the changing enterprise expectations and evolving Veeva product landscape, service providers are investing in building strong Veeva-specific solutions to expedite clients’ time-to-market . In this report, we analyze 15 IT service providers’ Veeva services capabilities. These service providers are classified as Leaders, Major Contenders, and Aspirants based on their positioning on the Everest Group PEAK Matrix® – a composite index of distinct metrics related to a provider’s capability and market impact. Scope Industry: life sciences Services: Veeva services Geography: global Service providers covered: Accenture, Aqurance, Atos, BASE life science, Capgemini, Cognizant, Conexus Solutions Inc., Deloitte, EPISTA Life Science, Genpact, HCL Technologies, Infosys, NNIT, PwC, and TCS Contents This report comprises three sections, each containing insights into the Veeva service provider landscape: Market trends for Veeva services Assessment of service providers for Veeva services on several capability and market success-related dimensions Enterprise sourcing considerations, highlighting the strengths and limitations of each service provider Membership(s) Life Sciences Information Technology Sourcing and Vendor Management

The life sciences BPO service provider profile compendium provides accurate, comprehensive, and fact-based profile snapshots of 13 service providers in the market. Specifically, the report allows for comparison of the service providers on their areas of strength and development. It helps current and potential buyers of life sciences BPO services to assess the service providers on the capabilities that they desire. Each five-page profile presents a comprehensive picture of a provider’s service suite, scale of operations, technology solutions, and delivery locations; along with Everest Group’s assessment of the provider. The compendium also sheds light on the global life sciences BPO service provider landscape. These 13 service providers include Accenture, Cognizant, Conduent, DXC Technology, Genpact, HCL, IBM, Indegene, Syntel, TCS, Tech Mahindra, Wipro, and WNS. Content Each service provider profile captures the following life sciences BPO-specific details: Service suite and scale of operations: key leaders, service suite, FTEs, revenue, and recent developments Delivery locations: city-level detail of key delivery locations across the world Capabilities and clients: major engagements, revenue split by geography, FTE split by process coverage & location, and number of contracts by buyer size Technology solutions: brief profiles of key technology solutions Everest Group assessment: the position of the service provider on the Everest Group PEAK Matrix™, market share & delivery capability assessment, and overall remarks on the capabilities of the service provider Membership(s) Healthcare & Life Sciences Business Process Outsourcing

The life sciences clinical and R&D market has been subject to significant turbulence because of several factors including falling R&D productivity, long cycle times, widespread regulatory amendments, and evolution of the patient-centric paradigm (with mobile computing, social media platforms, and “anytime-anywhere” information access). This combination of disruptive and legacy factors has driven life sciences firms to adopt next-generation technologies in the automation and analytics space, while also modernizing their legacy platforms and applications. As the technology mandate for life sciences enterprises evolves, so do their relationships with IT service providers. This, in turn, is driving the need for relevant research and market intelligence on demand and supply trends in life sciences outsourcing market. Everest Group’s life sciences outsourcing research program addresses this market requirement by analyzing the outsourcing trends and service provider capabilities specific to ITO in the life sciences vertical. As clinical and R&D business is gaining widespread traction due to changes in secular, regulatory, and business trends, this report exclusively focuses on the clinical and R&D business and analyzes capabilities of 18 IT service providers in this market. In this PEAK Matrix, we analyze the current trends and outlook of large, multi-year ITO relationships in the life sciences clinical and R&D IT services market. The report also provides specific insights into enabling a go-to-market strategy for clinical and R&D IT. This report is structured across five key sections: Introduction and overview Executive summary Summary of key messages Key takeaways: Buyer feedback for service providers Implications for key stakeholders Market trends in clinical and R&D services Accelerated collaboration R&D consolidation Precision medicine PEAK Matrix for life sciences clinical and R&D IT services Profiles of clinical and R&D IT service providers Everest Group has a complimentary five-page PEAK Matrix preview document for this service provider landscape report. Membership(s) Healthcare & Life Sciences IT Outsourcing

Introduction The healthcare landscape has been subject to significant turbulence on account of a gamut of factors, including escalating costs, widespread regulatory amendments, changing business models, and the evolution of the patient-centric paradigm (with mobile computing, social media platforms, and “anytime-anywhere” information access). This combination of disruptive and legacy factors has driven healthcare firms to adopt new technologies, and at the same time revamp their existing systems, processes, and interfaces. As the technology mandate for healthcare enterprises evolves, so do their relationships with IT service providers. This, in turn, is driving the need for relevant research and market intelligence on demand and supply trends in healthcare outsourcing across the three major market segments – payer, provider, and life sciences. Everest Group’s Healthcare and Life Sciences (HLS) IT research program addresses this market’s requirement by analyzing outsourcing trends and service provider capabilities specific to HLS IT. In this report, we analyze the capabilities of 16 IT service providers specific to clinical and R&D IT services in the global life sciences space. These service providers are mapped on the Everest Group Performance | Experience | Ability | Knowledge (PEAK) Matrix, which is a composite index of a range of distinct metrics related to a provider’s capability and market success. Scope of the analysis Industry: Life sciences (pharmaceuticals, medical devices, biotechnology, and other life sciences) Services: Clinical and R&D IT services Geography: Global Sourcing model: Third-party IT transactions; excludes shared services or Global In-house Centers (GICs) Contents This report is structured across four key sections, each providing insights into the life sciences clinical and R&D IT service provider landscape, with a specific focus on large-sized contracts: Clinical and R&D in life sciences Key themes Clinical and R&D IT framework – scope vs. enablers Value chain adoption Service lines driving IT demand across categories Deal analysis Life sciences clinical and R&D IT service provider landscape: Analysis of individual service provider capabilities in the life sciences clinical and R&D IT space along the following dimensions: Delivery capability: Scale Scope Domain investments Delivery footprint Innovation Buyer satisfaction Market success: Transaction activity Life sciences clinical and R&D IT PEAK Matrix 2015 and analysis of individual Matrix clusters: Mapping of life sciences clinical and R&D IT service providers on the Everest Group Performance | Experience | Ability | Knowledge (PEAK) Matrix Commentary on the specific characteristics of PEAK Matrix clusters (Leaders, Major Contenders, and Aspirants) Commentary on the capabilities of each service provider: Delivery capability characteristics (scale, scope, domain investments, delivery footprint, innovation, and buyer satisfaction) Market success characteristics (transaction activity) Implications for key stakeholders: Implications of the market dynamics and identified life sciences clinical and R&D IT service provider landscape characteristics for key stakeholders: Implications for service providers Implications for buyers Everest Group has a complimentary four-page PEAK Matrix preview document for this service provider landscape report.